Cambridge, UK, 15 May 2024: Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification, today announced the appointment of Hazel Jones as Chief Executive Officer, after a successful six-month tenure as interim CEO and COO. As COO and interim CEO Hazel has […]
Appointment forms part of ongoing plans for continued development of the GenLink3D genomics platform and formation of strategic commercial and academic partnerships
Key appointment supports company growth and strategic commercial and academic partnerships Cambridge, UK, 06 November 2023: Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Hazel Jones as Chief Operating Officer. Following a £10 million Series A financing in October 2022, […]
Falling Walls 2023 We are honoured to be selected as a winner in the Science Start-ups/ #FallingWallsVenture category of the Falling Walls Foundation #GlobalCall23! This recognition underscores our commitment to driving positive change in the life sciences. We are looking forward to connecting with fellow innovators and to discuss our exciting platform at the Falling Walls #ScienceSummit2023 in Berlin on 7–9 […]
GenLink3DTM provides the first high-resolution mapping of DNA interactions in 3D space, enabling the vast array of non-coding genetic variations to be deciphered into actionable disease biomarkers and treatment targets Funds will be used to rapidly generate deep datasets of novel diagnostic signatures and candidate therapeutic targets across multiple immune-related diseases for internal and external […]
We had a great day at OnHelix conference held at Babraham Institute focussed on translating research into diagnostics and therapeutics. #onhelix22 #3DGenomics
We are developing a technology to unlock the full potential of the 3D organisation of the #humangenome to identify #disease-associated #genetic interactions including those that are causal for disease susceptibility and progression.
We are proud to be awarded the Johnson & Johnson Innovation QuickFire Challenge Grant which recognises the potential of our functional genomics platform, GenLink3D™.
